China Apixaban Cas 503612-47-3,Apixaban Cas545445-44-1,Apixaban Cas 38560-30-4,Apixaban Cas 881386-01-2,Apixaban Cas 503615-03-0,Apixaban Cas 1267610-26-3 Supplier

China Apixaban API And Intermediates Suppliers

Apixaban is a novel oral factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer under the trade name Aldol, which is a novel oral anticoagulant. Apixaban prevents thrombin production and thrombosis by inhibiting an important clotting factor, Xa. On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a collaboration to develop apaxaban, a new oral anticoagulant owned by BRIstol-Myers Squibb, as an upgraded alternative to warfarin. Under the agreement, Pfizer will make an upfront payment of $250 million to Bristol-Myers Squibb for 60 percent of the total development cost of apisaban, effective January 1, 2007, and Bristol-Myers Squibb will pay the remaining 40 percent, resulting in co-development and marketing rights for the drug. In May 2011, Apixaban was approved for the prevention of venous thrombosis in adults undergoing elective hip or knee replacement surgery in 27 European Union countries, Iceland and Norway. On 20 November 2012, the European Commission approved aldol (apisaban) for the prevention of stroke and systemic circulation embolism in adult patients with NVAF who have one or more risk factors for wind Chemicalbook. Subsequently, FDA of Canada, Japan and the United States approved Aldol? Apixaban is indicated for the prevention of stroke and systemic circulation embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors. On April 12, 2013, ELIQUIS (apisaban), a new Anticoagulant Drug jointly developed by Bristol-Myers Squibb and Pfizer, was officially launched in China. Aldol is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement. Its marketing provides a safe and effective new alternative for clinical anticoagulation after orthopedic surgery, and brings good news to patients undergoing elective hip/knee replacement in China. Clinical studies have demonstrated that two oral doses of enoxaparin per day are better than one subcutaneous injection of enoxaparin 40mg per day. Apixaban 2.5mg is more effective in preventing venous thromboembolic events after hip or knee replacement surgery without increasing the risk of bleeding.

China Apixaban Cas 38560-30-4,Apixaban Cas 503615-03-0,Apixaban Cas 881386-01-2 ,Apixaban Cas 1267610-26-3,Apixaban Cas 536760-29-9,Apixaban Cas 545445-44-1,Good Stock Apixaban API Cas 503612-47-3,Commercial Apixaban BMS 562247-01,Best Quality Apixaban Eliquis etc.

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Apixaban API And Intermediates

Commercilized Apixaban Intermediate Cas 1267610-26-3

Commercilized Apixaban API Cas No 503612-47-3

Commercilized Apixaban Intermediate cas 536760-29-9

Commercilized Apixaban Cas No 27143-07-3

Commercilized Apixaban Intermediate cas 545445-44-1

Commercilized Apixaban Intermediate Cas 881386-01-2

Commercilized Apixaban Intermediate Cas 38560-30-4

Commercilized Apixaban Intermediate Cas 503615-03-0

Good stock Apixaban Intermediate Cas 503615-03-0

Best Quality Apixaban Intermediate Cas 38560-30-4

Apixaban Intermediates cas 536760-29-9

Best Quality Apixaban Intermediates Cas 881386-01-2

High Purity Apixaban Intermediate Cas 1267610-26-3

Best Quality Apixaban Intermediate Cas 27143-07-3

Commercilized Apixaban API Cas 503612-47-3

High Purity QC-2213 Apixaban Intermediates